Get access to our best features
Get Started
SubscribeLogin
Get access to our best features
Get Started
Published

Illuccix® Receives European Approval - Telix Pharmaceuticals (NASDAQ:TLX)

Summary by Benzinga
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This signific…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stock Markets

Stock Markets

Melbourne, Australia

Melbourne, Australia

Liège

Liège

Australia Economy

Australia Economy

Belgium Economy

Belgium Economy

Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2025 Snapwise Inc
News
For You
Search
BlindspotLocal